TABLE 4

Summary of evidence and outcomes reported by guidelines discussing baricitinib

GuidelinesRCTsOutcomes considered
ACTT-2 (NCT04401579) [6]COV-BARRIER (NCT04421027) [57]CostMortalityClinical recoveryDischargeSafetyTime to ICU admissionProgression to IMVOther
Guidelines recommending for the use of baricitinib in at least one population described
WHOa
COVID-19 Advisory Ontariob
AWMF
CIDSc
SITA/SIPd
J-SSCG
IDSAe
NIH
Guidelines recommending the use of baricitinib in clinical trials only
Government of Mexico

“✓”: guideline explicitly mentions evidence or outcome. Empty cell: guideline does not explicitly mention evidence or outcome. Organisations: AWMF: Association of the Scientific Medical Societies in Germany; CIDS: Clinical Infectious Disease Society; IDSA: Infectious Disease Society of America; J-SSCG: Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock; NIH: National Institutes of Health; SIP: Italian Society of Pulmonology; SITA: Italian Society of Anti-Infective Therapy; WHO: World Health Organization. Abbreviations: ICU: intensive care unit; IMV: invasive mechanical ventilation; NCT: National Clinical Trial; RCT: randomised controlled trial. Other outcomes considered: a: duration of IMV. b: progression to new noninvasive ventilation or high-flow oxygen. c: clinical status at day 15. d: need for noninvasive ventilation. e: disease progression (follow-up: 28 days), IMV-free days (follow-up; 60 days). Sources: AWMF, October 2021 [24]; CIDS, September 2021 [28]; COVID-19 Advisory Ontario, January 2022 [32]; Government of Mexico, August 2021 [35]; IDSA, October 2021 [36]; J-SSCG, September 2021 [37]; MoH Brazil, May 2021 [38]; NICE, January 2022 [8]; NIH, December 2021 [39]; SITA/SIP, May 2021 [40]; WHO, January 2022 [9].